Speaker illustration

Doctor Stephen Greene

Duke Clinical Research Institute, Durham (United States of America)

Member of:

European Society of Cardiology
Heart Failure Association

Dr. Greene is a heart failure cardiologist in the Division of Cardiology and Duke Clinical Research Institute, at the Duke University School of Medicine. Dr. Greene’s research focuses on improving quality of care and outcomes for patients with heart failure. He has been a co-investigator and co-author of multiple national and international heart failure trials studying medical therapies for heart failure, including the ASTRONAUT, SOCRATES-Reduced, COMPOSE, and TRANSFORM-HF trials. He has also led multiple analyses from national registries characterizing the quality of heart failure care in U.S. clinical practice, including studies leveraging the CHAMP-HF registry, American Heart Association’s Get With The Guidelines Heart Failure registry, and the VICTORIA registry. Dr. Greene’s collaborative work has led to more than 300 publications in peer-reviewed journals.

Clinician perceptions and reasons for non-use of guideline-directed medical therapy for heart failure with reduced ejection fraction in the United States

Event: ESC Congress 2023

Topic: Pharmacotherapy

Session: Pharmacotherapy in heart failure

Thumbnail

Audience Q&A

Event: ESC Congress 2023

Topic: Chronic Heart Failure

Session: Implementing heart failure guidelines with collaborative care

Thumbnail

Early/rapid initiation of GDMT- case vignette and discussion

Event: ESC Congress 2023

Topic: Chronic Heart Failure

Session: Implementing heart failure guidelines with collaborative care

Thumbnail

Addressing new guidelines - discussion

Event: ESC Congress 2023

Topic: Chronic Heart Failure

Session: Implementing heart failure guidelines with collaborative care

Thumbnail

Insights from the clinic: optimising post-event management with layers of protection

Event: ESC Congress 2023

Topic: Heart Failure with Reduced Ejection Fraction (HFrEF)

Session: Going beyond foundational therapy in HFrEF: what is the role of sGC stimulators?

Thumbnail

Effect of torsemide vs furosemide on quality of life in heart failure

Event: Heart Failure 2023

Topic: Pharmacotherapy

Session: Clinical trials update: diuretics and post discharge treatment

Thumbnail

Contemporary use of SGLT2i therapy among patients hospitalized for heart failure with reduced ejection fraction in the United States

Event: Heart Failure 2023

Topic: Heart Failure with Reduced Ejection Fraction (HFrEF)

Session: Chronic heart failure - pathophysiology and mechanisms 1

Thumbnail

First intermediate analysis of the CARE-HK in heart failure registry

Event: Heart Failure 2023

Topic: Pharmacotherapy

Session: Chronic heart failure - pharmacotherapy 2

Thumbnail

Risk of safety events considered potential barriers to utilization of guideline-directed medical therapy among patients with worsening heart failure and ejection fraction 30% or lower

Event: Heart Failure 2023

Topic: Pharmacotherapy

Session: Chronic heart failure - pharmacotherapy 1

Thumbnail

Heart failure across the range of preserved ejection fraction in United States clinical practice

Event: ESC Congress 2022

Topic: Epidemiology, Prognosis, Outcome

Session: Heart failure with preserved ejection fraction (HFpEF) 2

Thumbnail

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb